Tonight on ⁦ @PamelaBrownCNN⁩ I explained that emerging data finds that all of the US COVID19 vaccines work well vs the B.1.1.7 variant now accelerating across the country. The other variants having an additional E484K mutation, not so much, but..

But these other variants of concern for now are of secondary importance to B.1.1.7 in the US. Later the E484K VOCs from South Africa or Brazil may become an issue in the US and for that except one-time boosters later this year or in 2022.

In the meantime all attention must focus on B.1.1.7 now making young people sick, that’s why expanded EUA for adolescents 12-15 yo is important. Last time VRBPAC was not unanimous about the 16 and 17 year olds, we’ll see how they feel about adolescents

In additional news is the potential concern of cerebral venous thrombosis in adenovirus vectored vaccines, linked to AstraZeneca Oxford as a 1/100,000 severe adverse event, but also J&J being looked at